Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN
Journal of Urology | May 18, 2026 | Volume: 216 | Issue: 3 | Pages: 400-411
10.1097/ju.0000000000005126
| PMID 42150056